A topical formulation comprising a tetracycline comprises two separate parts: (i) a first part comprising a tetracyline in solid form suspended in a first vehicle； and (ii) a second part comprising a second vehicle in which the tetracycline is soluble. Preferably the tetracycline is crystalline minocycline base. Suitably, a neutral vehicle is used for the first part of the formulation. The two parts of the formulation may be packaged in separate containers and are preferably topically applied therefrom simultaneously.
